Provider Networks & IPAs

Provider networks, IPAs, and ACO-aligned specialists are facing a tighter 2027 economics picture as CMS proposes only a 2.4% Medicare outpatient/ASC base update while Part D pressures continue, including CMS’s move to end the Part D premium stabilization demonstration and signals of ongoing bid pressure—raising downstream risks for referral networks, ambulatory strategy, and total-cost-of-care contracts. Medicaid and specialty VBC models are also moving toward more explicit pharmacy-cost integration: Indiana plans GLP-1 coverage for select Medicaid members under the BALANCE model, while oncology stakeholders are emphasizing that value-based myeloma and cancer care must account for innovation adoption, biosimilars, benefit-channel shifts, and access equity rather than simple unit-price trend (HFMA on 2027 outpatient payments; Wakely on oncology spending trends).